| Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. | |
| | |
MedLine Citation:
|
PMID: 20813342 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Apolipoprotein E varepsilon4 (APOE varepsilon4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE varepsilon4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). METHODS: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE varepsilon4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. RESULTS: APOE varepsilon4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE varepsilon4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. CONCLUSIONS: These findings demonstrate that APOE varepsilon4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE varepsilon4 status needs to be accounted for in treatment trials of MCI. |
| | |
Authors:
|
Danielle C Whitehair; Abdullah Sherzai; Jennifer Emond; Rema Raman; Paul S Aisen; Ronald C Petersen; Adam S Fleisher; |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Alzheimer's & dementia : the journal of the Alzheimer's Association Volume: 6 ISSN: 1552-5279 ISO Abbreviation: Alzheimers Dement Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-03 Completed Date: 2010-12-20 Revised Date: 2011-09-13 |
Medline Journal Info:
|
Nlm Unique ID: 101231978 Medline TA: Alzheimers Dement Country: United States |
Other Details:
|
Languages: eng Pagination: 412-9 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 The Alzheimer |
Affiliation:
|
Department of Neurosciences, University of California, San Diego, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Apolipoprotein E4 / genetics* Cholinesterase Inhibitors / therapeutic use Cognition Disorders / drug therapy, genetics* Disease Progression Female Follow-Up Studies Genotype Humans Indans / therapeutic use Male Middle Aged Neuropsychological Tests Piperidines / therapeutic use Psychiatric Status Rating Scales Randomized Controlled Trials as Topic Retrospective Studies Vitamin E / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
U01 AG010483-19S1/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein E4; 0/Cholinesterase Inhibitors; 0/Indans; 0/Piperidines; 120011-70-3/donepezil; 1406-18-4/Vitamin E |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patie...
Next Document: Alzheimer's disease, a multifactorial disorder seeking multitherapies.